Metronomic chemotherapy – the use of relatively non-toxic low doses of conventional chemotherapy drugs administered at close and regular intervals without break periods – is gaining increasing interest as an alternative to conventional, high-dose and break-prone chemotherapy schedules.

In addition to its anti-cancer cell properties, metronomic therapy has an anti-angiogenic activity, and can be easily associated with combinations of targeted biological agents.

There are several clinical, randomised phase III trials underway around the world which are investigating and possibly validating the metronomic concept, and many phase I-II clinical studies are ongoing in different parts of the world, including middle-low income countries where the interest for the metronomic concept is steadily increasing.

The purpose of this meeting is to bring together a group of dedicated basic and clinical research investigators to discuss the latest preclinical and clinical studies in the field, with the goal of utilising metronomic chemotherapy more effectively in both paediatric and adult oncology patients and to rise new, exciting preclinical and clinical questions to young investigators.

The meeting is located in the vibrant scientific environment of the IEO-IFOM scientific campus in the heart of Milan, the city of Expo 2015, and complements the 2014 Milan Breast Cancer Meeting and the celebrations for the 20th anniversary of the European Institute of Oncology.